HIV adapts to CRISPR/Cas9 inactivation

Wang et al (2016) Cell Reports

On April 7th a Cell Reports published a study that determined CRISPR/Cas9 gene editing not only failed to inactivate HIV, but ultimately led to its ability to evade future cleavage.  Chen Liang’s group at the University of Montreal found that after CRISPR/Cas9 treatment, infected T-cells  still produced HIV particles.  After sequencing it was found that these new viral particles had small mutations near the site of CRISPR/Cas9 cleavage indicative of NHEJ repair.  Liang’s group hypothesizes that treatment with CRISPR/Cas9 failed to induce a mutation that inactivated the HIV genome while simultaneously mutating the guide RNA site preventing future CRISPR/Cas9 targeting with the same guide RNA.  Liang’s group suggests that for CRISPR/Cas9 to be an effective treatment multiple guide RNAs will be required.

Author: Advanced Analytical

Advanced Analytical Technologies, Inc. (AATI) simplifies complex genomics workflows to accelerate research and discovery in pharmaceuticals, life science, biofuels, biotechnology and healthcare.

Leave a Reply